The findings of this study have therapeutic potential for treatment of CPS1 deficiency and other UCD, such as N-acetyl-glutamate synthase (NAGS) deficiency. This evidence concerns the gene CPS1 and hyperinsulinemic hypoglycemia, familial, 4.